PHA SCR spike protein general aspects
(Die Seite wurde neu angelegt: „{{up|PHA pharmacophore by screened target}} {{up|PHA ACE2 drug design}} ---- function. drug development non rbd/ace2 targets on spike. ---- {{tp|p=33184246|t=…“)
Aktuelle Version vom 27. April 2021, 19:27 Uhr
| PHA pharmacophore by screened target |
| PHA ACE2 drug design |
function. drug development non rbd/ace2 targets on spike.
33184246 2020. Identification of a repurposed drug as an inhibitor of Spike protein of human coronavirus SARS-CoV-2 by computational methods.
33215965 2020. An innovative method for the selection of inhibitors of the viral spike-glycoprotein of the SARS-CoV.
33260370 2020. Repositioning of Ligands That Target the Spike Glycoprotein as Potential Drugs for SARS-CoV-2 in an In Silico Study.
33289334 2020. Repurposing potential of FDA approved and investigational drugs for COVID-19 targeting SARS-CoV-2 spike and main protease and validation by machine learning algorithm.
33292056 2020. Sensing the interactions between carbohydrate-binding agents and N-linked glycans of SARS-CoV-2 spike glycoprotein using molecular docking and simulation studies.
C7245990 ?. Structure-based drug designing for potential antiviral activity of selected natural products from Ayurveda against SARS-CoV-2 spike glycoprotein and its cellular receptor.
C7334662 2020. Computational evaluation of major components from plant essential oils as potent inhibitors of SARS-CoV-2 spike protein.
32658736 2020. Bioinformatics studies on a function of the SARS-CoV-2 spike glycoprotein as the binding of host sialic acid glycans.
| 32868983 2020. Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2. |
32910920 2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.
32931291 2020. Generation of SARS-CoV-2 S1 Spike Glycoprotein Putative Antigenic Epitopes in Vitro by Intracellular Aminopeptidases.
32936048 2020. Molecular basis of the potential interaction of SARS-CoV-2 spike protein to CD147 in COVID-19 associated-lymphopenia.
32979436 2020. The structure-activity relationship of the interactions of SARS-CoV-2 spike glycoproteins with glucuronomannan and sulfated galactofucan from Saccharina japonica.
33024075 2020. Salvianolic acid C potently inhibits SARS-CoV-2 infection by blocking the formation of six-helix bundle core of spike protein.
| 33052520 2020. Griffithsin with A Broad-Spectrum Antiviral Activity by Binding Glycans in Viral Glycoprotein Exhibits Strong Synergistic Effect in Combination with A Pan-Coronavirus Fusion Inhibitor Targeting SARS-CoV-2 Spike S2 Subunit. |
| 32963099 2020. In Silico Structure-Based Repositioning of Approved Drugs for Spike Glycoprotein S2 Domain Fusion Peptide of SARS-CoV-2: Rationale from Molecular Dynamics and Binding Free Energy Calculations. |
33072222 2020. Structure-Based Design of Novel Peptidomimetics Targeting the SARS-CoV-2 Spike Protein.
33073198 2020. Therapeutically Targeted Destabilization of the Quaternary Structure of the Spike Protein in the Dominant G614 Strain of SARS-CoV-2.
33082259 2020. Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain.
33087721 2020. Antibody-mediated disruption of the SARS-CoV-2 spike glycoprotein.
33089452 2020. Human Hematopoietic Stem, Progenitor, and Immune Cells Respond Ex Vivo to SARS-CoV-2 Spike Protein.
33103220 2020. Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein.
33134398 2020. Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping.
33135358 2020. Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVID-19.
33140706 2020. Targeting the initiation and termination codons of SARS-CoV-2 spike protein as possible therapy against COVID-19: the role of novel harpagide 5-O-beta-D-glucopyranoside from Clerodendrum volubile P Beauv. (Labiatae).
33147850 2020. Application of Humanized Zebrafish Model in the Suppression of SARS-CoV-2 Spike Protein Induced Pathology by Tri-Herbal Medicine Coronil via Cytokine Modulation.
33147968 2020. In Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2.
33152616 2021. Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus.
33154106 2020. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.
33154108 2020. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.
33160938 2020. Computational drug re-purposing targeting the spike glycoprotein of SARS-CoV-2 as an effective strategy to neutralize COVID-19.
33069672 2020. ADMET profile and virtual screening of plant and microbial natural metabolites as SARS-CoV-2 S1 glycoprotein receptor binding domain and main protease inhibitors.
